专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10017573B2 Anti-αβTCR antibody 有权
公开(公告)号：US10017573B2
公开(公告)日：2018-07-10
申请号：US14241099
申请日：2012-09-12
申请人： Daniel Snell , Andreas Menrad , Gina Lacorcia , Srinivas Shankara , Huawei Qiu , Clark Pan , Benjamin Kebble
发明人： Daniel Snell , Andreas Menrad , Gina Lacorcia , Srinivas Shankara , Huawei Qiu , Clark Pan , Benjamin Kebble
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2809 , C07K16/2893 , C07K2317/24 , C07K2317/31 , C07K2317/71 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to humanized monoclonal antibodies comprising the CDRs of murine antibody BMA031, which bind to the apTCR.CD3 complex and possess improved biological properties.

2. 发明申请

US20090117073A1 USE OF A FUSION PROTEIN TARGETING THE ED-B FIBRONECTIN DOMAIN FOR TREATMENT OF ATHEROSCLEROSIS 审中-公开
标题翻译：用于治疗ED-B FIBRONECTIN域的融合蛋白用于治疗甲状腺功能亢进症
公开(公告)号：US20090117073A1
公开(公告)日：2009-05-07
申请号：US11928692
申请日：2007-10-30
申请人： Andreas Menrad , Hans Dietrich Menssen , Kristof Graf
发明人： Andreas Menrad , Hans Dietrich Menssen , Kristof Graf
IPC分类号： A61K38/20 , A61K38/02 , A61K39/395
CPC分类号： A61K47/6843 , A61K47/6813 , C07K2319/01
摘要： The present invention relates to the use of a fusion protein comprising an antibody part which specifically recognises ED-B fibronectin, an effector part and optionally one or more fusion protein linker(s) and/or antibody linker(s), for the manufacturing of medicaments for the treatment and prevention of atherosclerosis
摘要翻译：本发明涉及包含特异性识别ED-B纤连蛋白的抗体部分，效应部分和任选的一个或多个融合蛋白连接体和/或抗体连接体的融合蛋白在制备中的用途用于治疗和预防动脉粥样硬化的药物

3. 发明申请

US20090081207A1 High affinity human and humanized anti-alpha5beta1 integrin function blocking antibodies with reduced immunogenicity 审中-公开
标题翻译：高亲和力人和人源化的抗α5beta1整合蛋白功能阻断具有降低的免疫原性的抗体
公开(公告)号：US20090081207A1
公开(公告)日：2009-03-26
申请号：US11802573
申请日：2007-05-23
申请人： ANDREAS MENRAD , JOERG WILLUDA , KLAUS BOSSLET , DIETER ZOPF , HEIKE PETRUL , STEFAN STEIDL , JOSEF PRASSLER , CORINNE PETIT-FRERE
发明人： ANDREAS MENRAD , JOERG WILLUDA , KLAUS BOSSLET , DIETER ZOPF , HEIKE PETRUL , STEFAN STEIDL , JOSEF PRASSLER , CORINNE PETIT-FRERE
IPC分类号： A61K39/395 , C07K16/18 , C12N9/96 , C12N15/11 , C12N15/00 , A61P31/00 , G01N33/574 , C12N5/06 , A01K67/027 , C12P21/04
CPC分类号： C07K16/2842 , A61K2039/505 , C07K2317/21
摘要： The present invention relates to recombinant human or humanized polypeptides which bind to α5β1 integrin with high affinity and blocking function. Further, diagnostic and pharmaceutic applications of the potypeptides are disclosed.
摘要翻译：本发明涉及以高亲和力和阻断功能结合α5β1整联蛋白的重组人或人源化多肽。此外，公开了肽的诊断和药物应用。

4. 发明授权

US07459470B2 N-oxide anthranylamide derivatives and their use as medicaments 失效
标题翻译： N-氧化物苯甲酰胺衍生物及其作为药物的用途
公开(公告)号：US07459470B2
公开(公告)日：2008-12-02
申请号：US10476755
申请日：2002-05-03
申请人： Alexander Ernst , Andreas Huth , Martin Krueger , Karl-Heniz Thierauch , Andreas Menrad , Martin Haberey
发明人： Alexander Ernst , Andreas Huth , Martin Krueger , Karl-Heniz Thierauch , Andreas Menrad , Martin Haberey
IPC分类号： A61K31/47 , C07D213/89
CPC分类号： C07D213/89 , C07D401/12 , C07D405/12
摘要： Substituted N-oxidanthranilamide derivatives, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis are described. The compounds according to the invention can be used as or in the case of psoriasis, Kaposi's sarcoma, restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.
摘要翻译：描述了取代的N-氧化邻氨基苯甲酰胺衍生物，其作为用于治疗由持续性血管生成触发的疾病的药剂的生产和用途被描述。根据本发明的化合物可以用作银屑病，卡波西肉瘤，再狭窄，子宫内膜异位症，克罗恩病，霍奇金病，白血病，牛皮癣，关节炎，如类风湿关节炎，血管瘤，血管纤维瘤; 眼睛疾病如糖尿病性视网膜病变，新生血管性青光眼; 肾脏疾病如肾小球性肾炎，糖尿病肾病，恶性肾硬化，血栓性微血管病综合征，移植排斥反应和肾小球病; 纤维化疾病，如肝硬化，肾小球膜细胞增生性疾病，动脉硬化，神经组织损伤，以及球囊导管治疗后血管再狭窄的抑制，血管修复术或机械装置用于保持血管开放的诸如例如作为免疫抑制剂的支架，作为无疤痕愈合的支持，老年角化病和接触性皮炎。在淋巴管生成的情况下，根据本发明的化合物也可以用作VEGFR-3抑制剂。

5. 发明授权

US07012081B2 Anthranyl amides and their use as medicaments 失效
标题翻译：氨基酰胺和它们作为药物的用途
公开(公告)号：US07012081B2
公开(公告)日：2006-03-14
申请号：US10275479
申请日：2001-05-07
申请人： Martin Krueger , Andreas Huth , Orlin Petrov , Dieter Seidelmann , Karl-Heinz Thierauch , Martin Haberey , Andreas Menrad , Alexander Ernst
发明人： Martin Krueger , Andreas Huth , Orlin Petrov , Dieter Seidelmann , Karl-Heinz Thierauch , Martin Haberey , Andreas Menrad , Alexander Ernst
IPC分类号： A61K31/47 , C07D215/00 , C07D217/00
CPC分类号： C07D213/80 , C07C237/40 , C07D211/26 , C07D211/32 , C07D211/62 , C07D217/22 , C07D265/26 , C07D309/04 , C07D309/06 , C07D317/72 , C07D401/12 , C07D405/12
摘要： Substituted anthranilamides and use thereof as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of anthranilamides are described.
摘要翻译：描述了取代的邻氨基苯甲酰胺及其用作治疗由持续血管发生引起的疾病的药物及其用于制备邻氨基苯甲酰胺的中间产物。

6. 发明申请

US20050221434A1 Receptor of the EDb-fibronectin domains 审中-公开
标题翻译： EDb-纤连蛋白结构域的受体
公开(公告)号：US20050221434A1
公开(公告)日：2005-10-06
申请号：US11105475
申请日：2005-04-14
申请人： Andreas Menrad , Alexander Redlitz , Marcus Kopplitz , Ursula Egner , Inke Bahr
发明人： Andreas Menrad , Alexander Redlitz , Marcus Kopplitz , Ursula Egner , Inke Bahr
IPC分类号： G01N33/50 , A61K6/08 , A61K38/00 , A61K48/00 , A61L27/00 , A61L31/00 , A61P43/00 , C07H21/04 , C07K14/705 , C07K14/78 , C07K14/82 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N7/00 , C12N15/09 , C12P21/08 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/574
CPC分类号： G01N33/57492 , A61K48/00 , A61K2039/5256 , C07K14/705 , C07K2317/24 , G01N2333/78
摘要： The invention relates to a protein that binds specifically to the EDb-fibronectin domains, process for screening compounds that bind to a receptor of the EDb-fibronectin domains or to EDb-fibronectin domains themselves, as well as the uses of protein.
摘要翻译：本发明涉及一种特异性结合EDB-纤连蛋白结构域的蛋白质，用于筛选结合至ED-纤连蛋白结构域的受体的化合物或ED β-纤连蛋白结构域本身以及蛋白质的用途。

7. 发明申请

US20050089941A1 Receptor of the EDb-fibronectin domains 审中-公开
公开(公告)号：US20050089941A1
公开(公告)日：2005-04-28
申请号：US10676049
申请日：2003-10-02
申请人： Andreas Menrad , Alexander Redlitz , Marcus Kopplitz , Ursula Egner , Inke Bahr
发明人： Andreas Menrad , Alexander Redlitz , Marcus Kopplitz , Ursula Egner , Inke Bahr
IPC分类号： G01N33/50 , A61K6/08 , A61K38/00 , A61K48/00 , A61L27/00 , A61L31/00 , A61P43/00 , C07H21/04 , C07K14/705 , C07K14/78 , C07K14/82 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N7/00 , C12N15/09 , C12P21/08 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/574 , C07K16/22
CPC分类号： G01N33/57492 , A61K48/00 , A61K2039/5256 , C07K14/705 , C07K2317/24 , G01N2333/78
摘要： The invention relates to a protein that binds specifically to the EDb-fibronectin domains, process for screening compounds that bind to a receptor of the EDb-fibronectin domains or to EDb-fibronectin domains themselves, as well as the uses of protein.

8. 发明授权

US06878720B2 VEGF receptor tyrosine kinase inhibitors 失效
标题翻译： VEGF受体酪氨酸激酶抑制剂
公开(公告)号：US06878720B2
公开(公告)日：2005-04-12
申请号：US10180289
申请日：2002-06-26
申请人： Karl-Heinz Altmann , Guido Bold , Pascal Furet , Paul William Manley , Jeanette Marjorie Wood , Stefano Ferrari , Francesco Hofmann , Jürgen Mestan , Andreas Huth , Martin Krüger , Dieter Seidelmann , Andreas Menrad , Martin Haberey , Karl-Heinz Thierauch
发明人： Karl-Heinz Altmann , Guido Bold , Pascal Furet , Paul William Manley , Jeanette Marjorie Wood , Stefano Ferrari , Francesco Hofmann , Jürgen Mestan , Andreas Huth , Martin Krüger , Dieter Seidelmann , Andreas Menrad , Martin Haberey , Karl-Heinz Thierauch
IPC分类号： C07D233/64 , A61K20060101 , A61K31/00 , A61K31/166 , A61K31/167 , A61K31/415 , A61K31/417 , A61K31/44 , A61K31/4409 , A61K31/443 , A61K31/444 , A61K31/47 , A61K31/4745 , A61K31/497 , A61K31/505 , A61P20060101 , A61P17/00 , A61P27/02 , A61P35/00 , A61P43/00 , C07C20060101 , C07C223/02 , C07C237/30 , C07C317/26 , C07D20060101 , C07D211/22 , C07D213/04 , C07D213/38 , C07D213/40 , C07D213/61 , C07D213/64 , C07D213/89 , C07D215/12 , C07D215/14 , C07D215/36 , C07D215/58 , C07D233/54 , C07D265/26 , C07D401/12 , C07D401/14 , C07D405/12 , C07D407/12 , C07D409/12 , C07D413/12 , C07D471/02
CPC分类号： A61K31/415 , A61K31/44 , A61K31/47 , C07D213/38 , C07D213/56 , C07D213/64 , C07D213/89 , C07D215/12 , C07D233/54 , C07D405/12
摘要： Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1 is aryl; R2 is a bicyclic heteroaryl group comprising one ring nitrogen atom with the exception that R2 cannot represent 2-phthalimidyl; any of R3, R4, R5 and R6, independently of the other, is H or a substituent other than hydrogen; and R7 and R8, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.
摘要翻译：描述的是式（I）的化合物，其中W是O或S; X为NR8; Y为CR 9 R 10 - （CH 2）n，其中R 9和R 10彼此独立地为氢或低级烷基，n为0〜3的整数。或Y为SO2; R1是芳基; R2是包含一个环氮原子的二环杂芳基，不同的是R 2不能代表2-邻苯二酰亚氨基; R 3，R 4，R 5和R 6中的任何一个独立地为H或氢以外的取代基; 且R 7和R 8彼此独立地为H或低级烷基; 或N-氧化物或其药学上可接受的盐在制备用于治疗对VEGF受体酪氨酸激酶活性的抑制作出反应的肿瘤疾病的药物产品中的用途。式（I）化合物可用于治疗，例如，的肿瘤疾病，如肿瘤疾病，视网膜病变和年龄相关性黄斑变性。

9. 发明申请

US20050054654A1 VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines 失效
标题翻译： VEGFR-2和VEGFR-3抑制性邻氨基苯甲酰胺吡啶
公开(公告)号：US20050054654A1
公开(公告)日：2005-03-10
申请号：US10870491
申请日：2004-06-18
申请人： Andreas Huth , Ludwig Zorn , Martin Krueger , Stuart Ince , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
发明人： Andreas Huth , Ludwig Zorn , Martin Krueger , Stuart Ince , Karl Thierauch , Andreas Menrad , Martin Haberey , Holger Hess-Stumpp
IPC分类号： C07D213/61 , C07D213/73 , C07D213/74 , C07D213/75 , C07D401/04 , C07D401/12 , C07D401/14 , C07D409/12 , C07D413/04 , C07D413/14 , C07D417/04 , C07D43/02 , A61K31/497 , A61K31/501 , A61K31/506 , C07D41/02
CPC分类号： C07D213/61 , C07D213/73 , C07D213/74 , C07D213/75 , C07D401/04 , C07D401/12 , C07D401/14 , C07D409/12 , C07D413/04 , C07D413/14 , C07D417/04
摘要： VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver; mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.
摘要翻译：描述了VEGFR-2和VEGFR-3抑制性邻氨基苯酰胺吡啶酰胺，其作为用于治疗由持续血管发生引起的疾病的药物的制备和用途，以及用于制备化合物的中间产物。根据本发明的化合物可用于或在肿瘤或转移生长的情况下，牛皮癣，卡波西肉瘤，再狭窄，例如支架诱导的再狭窄，子宫内膜异位，克罗恩病，霍奇金病，白血病; 关节炎，如类风湿关节炎，血管瘤，血管纤维瘤; 眼睛疾病如糖尿病性视网膜病变，新生血管性青光眼; 肾脏疾病如肾小球性肾炎，糖尿病肾病，恶性肾硬化，血栓性微血管病综合征，移植排斥反应和肾小球病; 纤维化疾病，如肝硬化; 肾小球膜细胞增生性疾病，动脉硬化，神经组织损伤，以及球囊导管治疗后血管假体中或使用机械装置用于保持血管开放（例如，支架）作为免疫抑制剂的抑制，作为免疫抑制剂无疤痕愈合，老年角化病和接触性皮炎的支持。在淋巴管生成的情况下，根据本发明的化合物也可以用作VEGFR-3抑制剂。

10. 发明授权

US06376480B1 Vitamin D derivatives with substituents at C-25, process for their production, intermediate products and use for the production of pharmaceutical agents 失效
标题翻译： C-25具有取代基的维生素D衍生物，其制备方法，中间产物和用于生产药剂的用途
公开(公告)号：US06376480B1
公开(公告)日：2002-04-23
申请号：US09738286
申请日：2000-12-18
申请人： Gerald Kirsch , Andreas Steinmeyer , Günter Neef , Katica Schwarz , Ruth Thieroff-Ekerdt , Herbert Wiesinger , Andreas Menrad , Martin Haberey
发明人： Gerald Kirsch , Andreas Steinmeyer , Günter Neef , Katica Schwarz , Ruth Thieroff-Ekerdt , Herbert Wiesinger , Andreas Menrad , Martin Haberey
IPC分类号： A61K3159
CPC分类号： C07C401/00
摘要： A method of preparing a pharmaceutical composition, comprising combining a pharmaceutically compatible vehicle with a compound according to formula (I)
摘要翻译：一种制备药物组合物的方法，包括将药学上相容的载体与式（I）化合物

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式